Since the expression of RBP4 and PLAC8 were increased in tumor cells in PC3-GFP/PC3-OPG-injected mice compared to controls, RBP4 and PLAC8 may be acting as survival factors in prostate cancer cells when osteolytic tumor growth is inhibited by OPG. Here, PLAC8 is linked to prostate carcinoma.